Agitation seen in dementia is among many of the common causes that lead to caregiver burnout and community/facility placement and can lead to resident quality of life issues. On Thursday, May 11th, the Food and Drug Administration approved, for the first time, a drug to treat agitation symptoms in Alzheimer’s disease. The drug, Rexulti, is an antipsychotic medication whose new approval covers its use as a once-daily treatment to ease emotional symptoms over time. This is the first FDA-approved treatment option for this indication.
Check out these articles from Alzheimer’s News Today, McKnights Long-Term Care News, and the FDA News Release for more information.
If you or an aging loved one is considering a move to an Assisted Living Facility for Memory Care Services in Smyrna GA please contact the caring staff at Woodland Ridge today. 770-431-7055
Latest posts by Woodland Ridge Staff (see all)
- Resident Spotlight – May 2024 - April 24, 2024
- The Core of CaraVita - April 24, 2024
- EMPLOYEE SPOTLIGHT – May 2024 - April 23, 2024
